A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs BA 3011 (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BioAtla
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 28 Feb 2018 Status changed from not yet recruiting to recruiting, according to a Bioatla media release.
- 28 Feb 2018 According to a Bioatla media release, first patient has been treated in this trial.